The anti-STEAP oncology landscape in one free database: 29 preclinical and clinical programs targeting STEAP1 and STEAP2, across mAbs, ADCs, bispecific and trispecific antibodies, CAR-T cells, and cancer vaccines — mapped by developer and clinical stage, spanning prostate, lung, and gastrointestinal cancers, Ewing sarcoma, and osteosarcoma.
27 preclinical and clinical programs targeting STEAP1 or STEAP2
STEAP1 (six-transmembrane epithelial antigen of the prostate 1) and its homolog STEAP2 are cell-surface metalloreductases that sit in the plasma membrane of epithelial cells. Both are overexpressed across several solid tumors — most consistently in prostate cancer — while their expression in normal tissue stays limited. That combination of tumor overexpression and an accessible extracellular surface opens a therapeutic window and makes them reachable by antibody- and cell-based drugs.
Interest now spans a range of modalities, from antibody-drug conjugates and bispecific and trispecific T-cell engagers to CAR-T cells and cancer vaccines. Programs reach beyond prostate cancer into lung and gastrointestinal tumors, Ewing sarcoma, and osteosarcoma, from preclinical work through late-stage clinical development.
Featured companies include:
AbbVie, Adcentrx Therapeutics, Amgen, AstraZeneca, Barinthus Biotherapeutics, BioNTech, Genentech, Henlius, Memorial Sloan Kettering, University of Pennsylvania, Xencor, Xilio Therapeutics
Need to discover or validate new targets, test your compounds, or analytical support for a trial?
Contact us